Mayzent vs. Glatopa

• Are Mayzent and Glatopa the Same Thing?
• What Are Possible Side Effects of Mayzent?
• What Are Possible Side Effects of Glatopa?
• What Is Mayzent?
• What Is Glatopa?
• What Drugs Interact with Mayzent?
• What Drugs Interact with Glatopa?
• How Should Mayzent Be Taken?
• How Should Glatopa Be Taken?

Mayzent (siponimod) and Glatopa (glatiramer acetate injection) are used to treat relapsing forms of multiple sclerosis (MS).

Glatopa is generic version of Copaxone.

Mayzent and Glatopa belong to different drug classes. Mayzent is a sphingosine 1-phosphate receptor modulator and Glatopa is an immunomodulator.

Side effects of Mayzent that are different from Glatopa include headache, high blood pressure (hypertension), increased liver transaminase, falls, pain and swelling in extremities, nausea, dizziness, diarrhea, and slow heart rate.

Side effects of Glatopa that are different from Mayzent include injection site reactions, skin redness, rash, hives, lightheadedness, flushing, palpitations, anxiety, indigestion, throat constriction, and chest pain.

Mayzent may interact with "live" vaccines, cancer medications, immune-modulating drugs, immunosuppressive therapies, anti-arrhythmics, QT prolonging drugs, calcium channel blockers, other drugs that may decrease heart rate, beta-blockers, fluconazole, rifampin, carbamazepine, modafinil, or efavirenz.

Glatopa may interact with other drugs.

Common side effects of Mayzent include:

• headache,
• high blood pressure (hypertension),
• increased transaminase,
• falls,
• swelling of extremities,
• nausea,
• dizziness,
• diarrhea,
• slow heart rate, and
• pain in extremities

Common side effects of Glatopa include:

• headache,
• tired feeling,
• influenza,
• stuffy nose,
• sinus pain,
• diarrhea,
• back pain,
• liver transaminase elevations, and
• cough.

Glatopa can affect your immune system's ability to fight an infection while you are taking the medication and for 2 months after your last dose. Tell your doctor right away if you develop signs of an infection such as:

• persistent cough or sore throat,
• difficulty breathing,
• fever,
• chills, or
• cold/flu symptoms.

Mayzent (siponimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Glatopa (fingolimod) is a sphingosine 1-phosphate receptor modulator used to treat patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of exacerbations and to delay physical disability.

Mayzent may interact with:

• "live" vaccines,
• cancer medications,
• immune-modulating drugs,
• immunosuppressive therapies,
• anti-arrhythmics,
• QT prolonging drugs,
• calcium channel blockers,
• other drugs that may decrease heart rate,
• beta-blockers,
• fluconazole,
• rifampin,
• carbamazepine,
• modafinil, or
• efavirenz.

Glatopa may interact with:

• beta-blockers,
• calcium channel blockers,
• citalopram,
• chlorpromazine,
• digoxin,
• erythromycin,
• haloperidol,
• ketoconazole,
• medications to control the immune system,
• medications for cancer, heart problems, or high blood pressure, and
• methadone

Tell your doctor all medications and supplements you use. Glatopa may cause fetal harm. It takes approximately 2 months for Glatopa to be eliminated from the body. Women should avoid pregnancy during treatment with Glatopa and for 2 months after treatment. It is not known if Glatopa passes into breast milk. Women and their doctors should decide whether to take Glatopa or breastfeed. Women should not do both.

Initiate Mayzent with a 5-day titration. The recommended maintenance dosage of Mayzent is 2 mg.

The recommended dose for Glatopa is 0.5 mg orally once daily, with or without food.